TrialBMJ open2016

Can recombinant human thrombomodulin increase survival among patients with severe septic-induced disseminated intravascular coagulation: a single-centre, open-label, randomised controlled trial.

Akiyoshi Hagiwara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.